Clinical Trial Update: Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing radium-223 dichloride with exemestane and Everolimus vs placebo with exemestane and Everolimus in bone-predominant HER2-negative HR-posi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Everolimus (everolimus)
• Exemestane (Exemestane)
• Radium-223 dichloride (radium-223 dichloride)

Snippet

Sponsor: Bayer | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2022-03-10